熱門資訊> 正文
指引调整后GoodRx暴跌21%，季度每股收益未达标
2024-08-09 00:39
- GoodRx (NASDAQ:GDRX) is down ~21% in Thursday trading after announcing a Q3 revenue guidance range that did not include the consensus and saying that prior full-year guidance will be in the low-end of the range.
- The company sees Q3 revenue of $193M-$197M (midpoint $195M), below the consensus estimate of $202.45M.
- For 2024, revenue is expected at the low end of its previous outlook of $800M-$810M (midpoint $805M). Consensus is $806.39M.
- In Q2, financial results were in-line on the top and a miss on the bottom line.
- On an adjusted basis, net income rose ~17% year over year to ~$32.4M ($.08 diluted EPS vs. $.07).
- As of the end of the quarter (June 30), GoodRx recorded 6.6M active monthly customers, compared to 6.1M in the year-ago period. However, subscription plans declined to 696K from 969K.
More on GoodRx Holdings
- GoodRx Q2 Earnings Preview
- GoodRx: Encouraging Profit Stabilization (Rating Upgrade)
- GoodRx Holdings Non-GAAP EPS of $0.08 misses by $0.01, revenue of $200.6M in-line
- GoodRx offers exclusive discount to biosimilar targeting AbbVie’s Humira
- Seeking Alpha’s Quant Rating on GoodRx Holdings
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
